Stay updated on Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial
Sign up to get notified when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.

Latest updates to the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page now displays the completed phase 2 study of interleukin-2 and pembrolizumab for metastatic kidney cancer, including its treatment plan, eligibility criteria, outcome measures, investigators, and study documents.SummaryDifference50%

- Check13 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden message instead of the study record.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedA site-wide NIH transition notice appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check41 days agoChange DetectedThe site revision indicator changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study content, indicating an access/permission issue that prevents viewing the record.SummaryDifference19%

- Check62 days agoChange DetectedThe page now displays the updated platform revision (v3.7.0) in place of the previous v3.6.6, indicating a site-wide update without altering the study details.SummaryDifference0.1%

Stay in the know with updates to Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Interleukin-2 & Pembrolizumab for Kidney Cancer Clinical Trial page.